

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 30/05/2019

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai-400001

Scrip Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, i.e. Thursday, 30th day of May, 2019 (commenced at 05:00 P.M. and concluded at 06:45 P.M.), has inter alia approved and passed the following resolutions:

1. Consideration and Approval of the Audited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended 31st March, 2019. **(Copy Enclosed)**
2. The Board considered and took on record, the Audit Report on Financial Results for the quarter and year ended 31st March, 2019 as placed by the Statutory Auditor of the Company. **(Copy Enclosed)**
3. Declaration of unmodified opinion on Auditor's Report on annual financial results for the quarter and year ended 31st March, 2019. **(Copy Enclosed)**
4. The Board had appointed M/s Jain P & Associates, Practicing Company Secretaries, as Secretarial Auditor for the financial year 2018-19.
5. The Board took note of Statement of Investor Complaints/Grievances given Under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended 31st March, 2019.

Kindly take the above information on your records.

Thanking you,

For Raymed Labs Limited

Ajai Goyal

Whole Time Director

DIN: 02636418

Statement of Audited Standalone Assets and Liabilities

Particulars	Amount (In Lakhs)	
	As at 31st March, 2019	As at 31st March, 2018
	(Audited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	17.29	17.92
(b) Financials Assets-		
(i) Investments	0.00	0.00
(ii) Trade Receivables	0.00	0.00
(iii) Loans	0.00	0.00
(iv) Other	0.00	0.00
(c) Deferred tax assets (net)	0.00	0.00
(d) Other non-current assets	0.00	0.00
Current Assets		
(a) Inventories	0.00	0.00
(b) Financials Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	2.49	2.49
(iii) Cash and cash equivalents	0.14	0.03
(iv) Bank Balance other than (iii) above	0.03	0.03
(v) Loans	6.10	6.10
(vi) Others	0.45	0.45
(c) Current tax Assets	0.00	0.00
(d) Other current Assets	0.00	0.00
TOTAL ASSETS	26.50	27.02
EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	-620.19	-614.84
Liabilities		
Non -Current liabilities		
(a) Financials Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payable	0.00	0.00
(iii) Other Financial liabilities	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deffered Tax Liabilites (net)	0.00	0.00
(d) Other Non-Current Liabilities	0.00	0.00
Current Liabilities		
(a) Financials Liabilities		
(i) Borrowings	199.85	198.80
(ii) Trade Payables	5.54	4.80
(iii) Other Financial liabilities	5.00	5.00
(b) Other current liabilities	8.95	5.92
(c) provisions	0.00	0.00
(d) Current Tax Liablitries	0.00	0.00
TOTAL EQUITY AND LIABILITES	26.50	27.02

For Raymed Labs Limited

Ajai Goyal

Ajai Goyal
 Whole Time Director
 DIN: 02636418

Add: 103 Emperor 1, Supertech Emerald Court,
 Sector 93A Noida, UP – 201304

Date: 30.05.2019
 Place : Noida




Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2019

Particulars	Amt. (In Lakhs)				
	Quarter Ended			Year Ended	
	31st March, 2019	31st Dec, 2018	31st March, 2018	31st March, 2019	31st March, 2018
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from Operations	0.00	0.00	0.00	0.00	0.00
II. Other Income	0.33	0.33	0.30	1.26	1.20
III. Total Income (I +II)	0.33	0.33	0.30	1.26	1.20
IV. Expenses					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.60	0.30	0.23	1.35	1.06
Finance Costs	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	0.16	0.16	0.17	0.64	0.68
Other Expenses	0.52	0.46	0.79	1.68	2.26
Total Expenses (IV)	1.27	0.92	1.19	3.66	4.00
V. Profit/(Loss) before exceptional items and tax (III- IV)	-0.94	-0.59	-0.89	-2.40	-2.80
VI. Exceptional items	0.00	0.00	0.00	2.95	2.88
VII. Profit/(Loss) before tax (V-VI)	-0.94	-0.59	-0.89	-5.35	-5.68
VIII. Tax Expense					
(1) Current tax	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-0.94	-0.59	-0.89	-5.35	-5.68
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-0.94	-0.59	-0.89	-5.35	-5.68
XIV. Other Comprehensive Income					
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)	-0.94	-0.59	-0.89	-5.35	-5.68
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)					
XVI. Earnings per equity share (for continuing operation):					
(1) Basic	-0.02	-0.01	-0.02	-0.12	-0.13
(2) Diluted	-0.02	-0.01	-0.02	-0.12	-0.13
XVII. Earnings per equity share (for discontinued operation):					
(1) Basic	0.00	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00	0.00
XVIII. Earnings per equity share (for discontinued & continuing operations)					
(1) Basic	-0.02	-0.01	-0.02	-0.12	-0.13
(2) Diluted	-0.02	-0.01	-0.02	-0.12	-0.13

Notes:

- (1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 30, May 2019. The Statutory Auditors have carried out their audit for the above results.
- (2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- (3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- (4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
- (5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.
- (6) Figures of the quarter ended 31st March, 2019 and 31st March, 2018 are balancing figures between audited figures in respect of full financial year and the year to date figures upto third quarter of the relevant financial year which were subject to limited review by the auditors.

For Raymed Labs Limited



Ajal Goyal
 Whole Time Director
 DIN: 02636418
 Add: 103 Emperor 1, Supertech Emerald Court,
 Sector 93A Noida, UP – 201304

Date: 30.05.2019

Place : Noida



A. Kay Mehra & Co.

CHARTERED ACCOUNTANTS

2470 (Basement), Hudson Line, GTB Nagar, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

Independent Auditor's Report on Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Raymed Labs Limited

1. We have audited the accompanying Statement of Financial Results of Raymed Labs Limited ("The Company") for the quarter and year ended 31st March, 2019 ("The Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related Ind AS financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the these quarterly and year to date financial results:
- i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
 - ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net loss and other financial information of the Company for the quarter and year ended 31st March, 2019.
5. The Statement includes the results for the quarter ended March 31, 2019 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the of the current year which are subject limited review by us.

Place: Noida
Date: May 30, 2019

For A Kay Mehra & Co.
Chartered Accountants
(F.R.N. 050004C)

Deepak
Suneja

Digitally signed
by Deepak Suneja
Date: 2019.05.30
18:42:07 +05'30'

CA Deepak Suneja
Partner
(Membership No. 501957)

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP- 201304, **Website-** www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, **Phone no.** - 0120-2426900, 9412700300

30.05.2019

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street, Fort

Mumbai- 400001


Sub: Declaration on Audit Report for the year ended 31st March, 2019

Dear Sir/Madam,

We hereby declare, on behalf of **Raymed Labs Limited** that Audit report in respect to Annual Audited Financial Results for the period ended 31st March, 2019 submitted by A. Kay Mehra & Co., Statutory Auditor of the Company is with unmodified opinion of the Statutory Auditor.

Sincerely,

For Raymed Labs Limited



Ajai Goyal

DIN: 02636418

Whole Time Director

Add: 103, Emperor 1

Supertech Emerald Court

Sector-93A, Noida U.P.-201304